Knowledge Center

Accessing and standardizing raw clinical data across multiple hospitals presents a challenge in Oncology. However, it is crucial to use real-world data sources such as electronic health records (EHR) to leverage untapped information. We are building a federated data network to facilitate GDPR-compliant data exchange of large datasets, with hospitals as owners. This network, governed by a common data model (CDM), is aimed at fostering multicenter, observational, real-world evidence (RWE) studies in Oncology, with breast cancer, lung cancer, and immunotherapy as therapeutic areas of focus.

This study aimed to investigate the prevalence of impaired renal function at the time of Heart Failure diagnosis and its correlation with short and long-term outcomes in a real-world cohort of Heart Failure patients.

NLP algorithms allow rapid data extraction from pathology reports, thereby offering a time-efficient and cost-effective alternative to manual data processing. In turn, this approach enables rapid insight in current biomarker testing rates and prevalence of (actionable) mutations.

Information held in Electronic Health Records (EHRs) hold a significant opportunity to provide physicians and researchers with better and more insights to improve disease management and treatment.

The study aimed to analyze individuals with ATTR-CM in a real-world heart failure patient population using a federated OMOP-CDM database generated from data of electronic health records.

RWE is becoming a valuable addition to randomized controlled clinical trials to better understand the mechanisms and outcomes of cancer treatments. However, most RWD is locked in a non-uniform patient reporting system by hospitals and healthcare professionals. Download our use case in immuno-oncology by completing the form and read how artificial intelligence can help unlock real-world evidence in immunotherapy.

Discover how combining clinical expertise, real-world data and technology can save lives of heart failure patients.

An example of the power of real-world data, technology and collaboration to transform patient care. The study aimed to shed light on patient eligibility for SGLT2 inhibitors as a therapy for heart failure patients, providing valuable information for clinicians and researchers.

The diagnostic delay for rare disease patients can go up to more than 5 years. But were you aware that technology could play a significant role in speeding up the diagnosis time of rare diseases?